Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurosci Lett ; 660: 79-85, 2017 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-28893593

RESUMO

The genus Passiflora is popularly used to treat anxiety. Recent studies showed antidepressant-like effects of two varieties of P. edulis (edulis and flavicarpa) in mice. However, the mechanisms of antidepressant actions are still unknown. Here, the effects of P. edulis fo. edulis aqueous extract (AE, 100-300mg/kg, po), and ethyl acetate (AcOEt, 25-50mg/kg, po), butanol (BuOH, 25-50mg/kg, po) and residual aqueous (25-100mg/kg, po) fractions were investigated in the mouse forced swimming test. In addition, the involvement of monoamines in the P. edulis fractions-induced antidepressant actions was approached. HPLC analyses showed that AcOEt and BuOH, but not residual, fractions shared with AE the main peaks between 25 and 70min (UV 340nm), which are suggestive of flavonoids. Nortriptyline and fluoxetine reduced the immobility time and similar results were observed for AE, AcOEt and BuOH but not residual fractions. PCPA (inhibitor of 5-HT synthesis), AMPT (inhibitor of catecholamine synthesis) and sulpiride (selective D2 receptor antagonist), but not DSP-4 (noradrenergic neurotoxin), blocked the antidepressant actions of AcOEt and BuOH. In conclusion, AcOEt and BuOH fractions shared with AE similar phytochemical composition and antidepressant actions. Preserved 5-HT and dopamine transmissions were required for the antidepressant effects of P. edulis fractions.


Assuntos
Antidepressivos/administração & dosagem , Monoaminas Biogênicas/metabolismo , Depressão/metabolismo , Passiflora/química , Extratos Vegetais/administração & dosagem , Transmissão Sináptica , Acetatos/administração & dosagem , Animais , Antidepressivos/isolamento & purificação , Antidepressivos de Segunda Geração/administração & dosagem , Antidepressivos Tricíclicos/administração & dosagem , Comportamento Animal , Benzilaminas/administração & dosagem , Butanóis/administração & dosagem , Catecolaminas/antagonistas & inibidores , Catecolaminas/metabolismo , Depressão/tratamento farmacológico , Antagonistas de Dopamina/administração & dosagem , Fluoxetina/administração & dosagem , Masculino , Camundongos , Nortriptilina/administração & dosagem , Extratos Vegetais/isolamento & purificação , Sulpirida/administração & dosagem
2.
Exp Clin Psychopharmacol ; 25(2): 105-113, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28287793

RESUMO

Anxiety disorders are associated with increased impairments in psychosocial functioning, work productivity and health-related quality of life. In addition, anxiety is a common symptom of ethanol withdrawal and it strongly contributes to relapse. Benzodiazepines are frequently prescribed for relief of anxiety and ethanol withdrawal symptoms but considerable side effects, such sedation, tolerance and dependence, are observed during treatment. Therefore, better drugs are needed for the treatment of anxiety states. The purpose of this study was to investigate whether topiramate would reduce basal levels of anxiety and ethanol-withdrawn induced anxiety in male rats; the elevated plus maze (EPM) was used as an animal model of anxiety. In Experiment 1, topiramate (0, 10, and 40 mg/kg, i.g.) and diazepam (1 mg/kg, i.p.) was acutely and repeatedly administered to naive rats. In Experiments 2 and 3, topiramate (0 or 40 mg/kg, i.g.) was acutely and chronically administered in early (72 hr after ethanol removal) and protracted (21 days after ethanol removal) ethanol-withdrawn rats, respectively. Acute and repeated topiramate treatment induced anxiolytic-like effects in naive rats. Early ethanol withdrawal increased anxiety, and acute topiramate administration counteracted the anxiogenic-like effects of ethanol removal. Protracted withdrawal did not produce lasting changes in anxiety but topiramate was equally effective at reducing anxiety in ethanol-withdrawn and control animals. Importantly, no signs of tolerance to the anxiolytic effects of topiramate were observed. In conclusion, these data support a role for topiramate in the treatment of basal levels of anxiety and ethanol withdrawal-induced anxiety. (PsycINFO Database Record


Assuntos
Ansiolíticos/farmacologia , Ansiedade/tratamento farmacológico , Frutose/análogos & derivados , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Animais , Ansiolíticos/administração & dosagem , Ansiedade/etiologia , Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/etiologia , Comportamento Animal/efeitos dos fármacos , Diazepam/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Etanol/administração & dosagem , Etanol/efeitos adversos , Frutose/administração & dosagem , Frutose/farmacologia , Masculino , Ratos , Ratos Wistar , Topiramato
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...